Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Recurrence

Colorectal Neoplasms

Adenocarcinoma

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Disease Attributes

Anti-Infective Agents

All Drugs and Chemicals

Formaldehyde

Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort

Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort

Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort

Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort

A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)

Tw1CE

Ajay Goel, PhD

Takayuki Noma, MD

Alessandro Mannucci

Mitsuo Shimada, PhD

Katsuki Miyazaki

Yuma Wada, PhD

Mistuo Shimada, PhD

Maria Pellise

Karmele Saez de Gordoa

María Daca

Francesc Balaguer

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC.

This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

The incidence of invasive submucosal colorectal cancer (T1 CRC) is increasing, likely as a reflection of improved screening and endoscopy use. Current treatment options for T1 CRC focus on less invasive methods (i.e., endoscopic submucosal dissection), and treatment decisions are based on the risk of lymph node metastasis (LNM). Up to 70-80% of T1 CRC patients may undergo surgery, with adjuvant chemotherapy recommended only for those with LNM.

However, current clinical practice guidelines are considered to be overly aggressive and recommend the administration of aggressive treatment to many patients who may be cured with non-invasive therapy alone. This results in the overtreatment of many patients, especially those that are currently defined as 'high-risk' T1 CRC. Existing surveillance methods may not adequately predict the prognosis of T1 CRC, lacking established biomarkers for assessing disease-free survival.

This study seeks to validate tissue-based biomarkers (micro-RNA and messenger RNA) that are associated with tumor recurrence after curative resection. The identification of patients at high risk of recurrence may help in the selection of patients who truly benefit from additional oncologic surgery or adjuvant therapy. Previous research by this group has identified miRNA signatures for detecting postoperative tumor recurrence and metastasis in CRC, highlighting their potential as biomarkers for disease progression.

Formalin-fixed, paraffin-embedded slide from the primary tumor

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

Predicting Recurrence After Curative-Intent Resection of T1 Colorectal Cancer With Transcriptomics

Data collected for the study will be made available to others, including de-identified participant data, at publication, via a signed data access agreement and at the discretion of the investigators' approval of the proposed use of such data.

Time from curative-intent resection to the development of recurrence (or death)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Predicting Local and Distant Recurrence in T1 Colorectal Cancer	NCT06314971	Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Neop... Colorectal Canc...	Tw1CE	18 Years -	City of Hope Medical Center
Predicting Local and Distant Recurrence in T1 Colorectal Cancer	NCT06314971	Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Neop... Colorectal Canc...	Tw1CE	18 Years -	City of Hope Medical Center

Spots Global Cancer Trial Database for tw1ce

Every month we try and update this database with for tw1ce cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tw1ce

Every month we try and update this database with for tw1ce cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tw1ce cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.